Skip to main navigation Skip to search Skip to main content

The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer

  • Francisco J. Sánchez-Martín
  • , Beatriz Bellosillo
  • , Mariona Gelabert-Baldrich
  • , Alba Dalmases
  • , Israel Cañadas
  • , Joana Vidal
  • , Alejandro Martinez
  • , Guillem Argilés
  • , Giulia Siravegna
  • , Sabrina Arena
  • , Klaus Koefoed
  • , Laura Visa
  • , Oriol Arpí
  • , Ivan David Horak
  • , Mar Iglesias
  • , Christopher Stroh
  • , Michael Kragh
  • , Ana Rovira
  • , Joan Albanell
  • , Josep Tabernero
    • Alberto Bardelli, Clara Montagut
  • University of Extremadura
  • Hospital del Mar
  • Vall d'Hebron Institute of Oncology
  • IRCCS Fondazione del Piemonte per l'Oncologia - Candiolo (TO)
  • University of Turin
  • Symphogen A/S
  • Merck KGaA
  • Pompeu Fabra University

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry